Endo Health downgraded to Underweight from Neutral at Piper Jaffray

theflyonthewall.com

Piper Jaffray downgraded Endo Health to Underweight citing Opana and Lidoderm generic competition risk. Piper thinks a company buyout is unlikely and lowered its price target for shares to $22 from $28.

View Comments (0)